Longterm outcomes of surgery for advanced ovarian cancer during interval cytoreduction
- 作者: Sekerskaya M.N1, Nikogosyan S.O1, Shevchuk A.S1, Kuznetsov V.V1, Kantieva D.M2, Tarachkova E.V2
-
隶属关系:
- N.N. Blokhin National Medical Research Center of Oncology
- Russian Medical Academy of Postgraduate Education" of the Ministry of Health of Russia
- 期: 编号 1S (2020): Supplement
- 页面: 44-49
- 栏目: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248765
- DOI: https://doi.org/10.18565/aig.2020.1suppl.44-49
- ID: 248765
如何引用文章
详细
全文:
作者简介
M. Sekerskaya
N.N. Blokhin National Medical Research Center of Oncology
Email: gynoncol6@gmail.com
S. Nikogosyan
N.N. Blokhin National Medical Research Center of Oncology
A. Shevchuk
N.N. Blokhin National Medical Research Center of Oncology
Email: gynoncol6@gmail.com
V. Kuznetsov
N.N. Blokhin National Medical Research Center of Oncology
Email: gynoncol6@gmail.com
D. Kantieva
Russian Medical Academy of Postgraduate Education" of the Ministry of Health of Russia
E. Tarachkova
Russian Medical Academy of Postgraduate Education" of the Ministry of Health of Russia
参考
- Horowitz N.S., Larry M.G., Miller A., C.A. Hamilton, B. Rungruang, N. Rodriguez, et a7, Predictive modeling for determination of microscopic residual disease at primary cytoreduction: an NRG Oncology/Gynecologic Oncology Group 182 Study, Gynecol. Oncol. 2018; 148(1): 49-55. doi: 10.1016/j.ygyno.2017.10.011
- Whitney C.W., Spirtos N. Gynecologic Oncology Group Surgical Procedures Manual. 2010 January: [Электронный документ] (https:// gogmember.org/ manuals/pdf/surgman.pdf).
- Peiretti M., Zanagnolo V., Aletti G.D., Bocciolone L., Colombo N., Landoni F. et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubalcancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol. 2010; 119(2): 259-64. http://dx.doi. org/10.1016/j.ygyno.2010.07.032
- Mueller J.J., Zhou Q.C., Iasonos A., R.E. O’Cearbhaill, F.A. Alvi, H.A. El, et al., Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol. 2016;140: 436-42.
- Wallace S., Kumar A., Mc Gree M., Weaver A. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecol Oncol. 2017; 145(1): 21-26. doi: 10.1016/j.ygyno. 2017.01.029. Epub 2017 Jan 31.
- Vergote I., Trope C.G., Amant F., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363: 943-53. doi: 10.1056/NEJMoa0908806
- Kehoe S., Hook J., Nankivell M., et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386: 249-57. doi: 10.1016/S0140-6736(14)62223-6.
- Chi D.S., Eisenhauer E.L., Zivanovic O., et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009; 114: 26-31. doi: 10.1016/j.ygyno.2009.03.018